Cell harvesting may appear to be a routine laboratory procedure, but its implications in downstream bioprocessing are far beyond standard. The decision between the established trypsin and the gentler accutase enzymes extends beyond protocol preference and can extend onto manufacturing capacity. Whether revisiting fundamentals or evaluating large-scale applications, the discussion around trypsin vs. accutase remains highly relevant within modern cell harvesting methods.
When compared to non-enzymatic cell harvesting methods, both trypsinization and accutase treatment are seen as more powerful when retrieving the majority of cell types. © Green Elephant Biotech.
Within biomanufacturing workflows, cell harvesting serves as a critical transition point between upstream expansion and downstream purification and formulation. In applications such as cell and gene therapy (CGT) production, harvesting must balance impurity removal, product quality, and yield — 3 parameters that directly affect clinical safety and manufacturing reproducibility (1).
Enzymatic dissociation remains the predominant strategy for detaching adherent cells. Trypsin and accutase are among the most widely used reagents. Trypsin, a serine protease, cleaves peptide bonds to disrupt cell-cell and cell-substrate interactions. The enzyme’s optimal activity at 37°C explains its physiological role in the human duodenum, where trypsin supports protein digestion (2).
Accutase, in contrast, is a non-mammalian proteolytic and collagenolytic enzyme mixture designed as a gentler alternative. Frequently selected for sensitive or primary cells, accutase does not require external neutralization and is reported to better preserve surface markers critical for cellular identity and downstream functionality (3).
The choice between trypsin vs. accutase directly affects cell viability, membrane protein integrity, and reproducibility. At higher processing densities — exceeding 20 million cells/mL — cell harvesting methods can also influence facility throughput and, consequently, patient access to advanced therapies. This article evaluates how each agent shapes cell harvesting in downstream processing and the broader biomanufacturing landscape.
Trypsin cell culture illustrates how one size does not fit all
First described in 1876, the name “trypsin” derives from the Greek thrýpto, meaning “to break apart.” This enzymatic activity quickly established trypsin as a cornerstone of cell culture protocols, including harvesting, passaging, and cryopreservation. Standard concentrations range between 0.025% and 0.05%, often combined with EDTA to mediate Ca²⁺ and Mg²⁺ ions that stabilize adhesion molecules (3).
While trypsin offers high efficiency and cost-effectiveness, its proteolytic strength can produce unintended effects. Exposure time and concentration determine whether detachment is controlled or detrimental. Excessive treatment may degrade membrane proteins, disrupt cytoskeletal architecture, and alter actin filament organization, compromising downstream performance (4).
Neutralization with fetal bovine serum (FBS) mitigates excessive proteolysis, however, certain cell types remain particularly sensitive to trypsin. Induced pluripotent stem cells (iPSCs) and immune cells such as macrophages and neutrophils rely heavily on surface marker integrity, rendering them less suitable for conventional trypsinization (5).
Although trypsin remains attractive due to its simplicity and established regulatory history, intensified CGT production environments demand tighter control of variability. Over-digestion events that introduce batch-to-batch inconsistency may be reduced by validated alternatives better suited for sensitive cell populations.
Accutase is an alternative with the potential to turn into a limitation
Unlike trypsin, accutase self-inactivates at 37°C and does not require serum-based neutralization. This simplifies workflows and reduces reagent dependencies. Its gentler activity better preserves surface proteins, including receptors such as Fas on macrophages — an advantage in flow cytometry and functional cell-based assays (5).
In comparative studies involving human mesenchymal stromal/stem cells (hMSCs), accutase achieved complete detachment in approximately 120 seconds, compared to 360 seconds for trypsin under similar conditions (6). Although yield improvements were reported, comprehensive quality assessments were not the primary endpoint of these investigations.
Despite these advantages, accutase is less frequently adopted in routine mammalian manufacturing. Higher costs, more stringent storage requirements (typically at 4°C), and supplier dependency contribute to its selective use. Moreover, accutase does not entirely eliminate risks of protein modification or contamination (7).
Accutase therefore occupies a defined but specialized role, particularly in stem and primary cell applications where preservation of phenotype outweighs cost considerations. Its broader industrial applicability must be evaluated in the context of scalability and validated process robustness.
Cell harvesting methods will continue to evolve – slower, but at a greater scale
In therapeutic bioprocessing, the choice of cell harvesting in downstream processing directly affects subsequent purification and formulation steps. Manufacturers must minimize cellular damage while maximizing yield and recovery (1). The appropriate method depends on intrinsic cell characteristics, extending beyond the binary trypsin vs. accutase discussion (3).
Trypsin-based dissociation remains prevalent in large-scale therapeutic cell and viral vector production due to scalability and regulatory familiarity. Transitioning away from established trypsin cell culture workflows would necessitate re-optimization and re-validation — an operationally demanding undertaking. In CGTs, however, TrypLE(™) – a recombinant fungal trypsin-like protease, has gained traction due to its gentler properties and self-deactivating nature similar to accutase. Though known to preserve the surface of primary cells, comparison of trypsin-based and TrypLE(™)-based workflows in keratinocyte harvesting deemed both workflows as comparably efficient (8).
Conversely, accutase has gained traction in clinical contexts requiring preserved cell surface markers, including fluorescence-activated cell sorting (FACS). FACS supports single-cell analysis, detection of abnormal proliferation, and precise quantification in immunotherapy manufacturing (9).
Looking forward, the industry recognizes that harvesting efficiency must align with the transition toward closed systems. As one expert proposed: “Either cell collection procedures will continue to evolve to support large-scale processes, or culture vessels will be engineered specifically for the purpose of cell collection” (10).
Selecting between trypsin and accutase is not merely a technical preference, but a strategic decision within cell harvesting in downstream processing. Trypsin is a classic and cost-effective solution, suited for large-scale manufacturing workflows. Accutase offers improved preservation of cell integrity and surface marker expression, making it valuable for sensitive stem and primary cell applications. With today’s harvesting methodologies becoming less self-sustained due to manual handling, additional emphasis must be placed on the suitability of automated systems for the dissociation enzyme of choice (9).
As manufacturing demands intensify and closed processing becomes standard, harvesting strategies must align with product integrity and scalability demands. Consequently, future innovation would lie in cultivation systems, engineered specifically for effective detachment and recovery, not just the enzymatic refinement.
What is CellScrew® suitable for?
CellScrew® was engineered to address the structural requirements of anchorage-dependent cells by providing increased surface area without compromising harvesting performance. Independent of whether trypsin or accutase is selected, the harvesting workflow remains consistent, while operational complexity and carbon footprint are reduced by 30% and 90% respectively. Harvesting data for adherent cell lines, such as HEK293 and CHO-K1, demonstrate the suitability of the CellScrew® series in seed train expansion among available applications.
With its Configurable Closed Transfer (CCT) extension, CellScrew® enables closed system processing and facilitates large-scale cell production while upkeeping product quality and yield. Find out how CellScrew® CCT can preserve your resources in research-to-clinical journey on Green Elephant Biotech showcase page.
References:
- Cell Harvesting Steps Separate the Good from the Bad. (2020). Cynthia A. Challener, BioPharm International. Available https://www.biopharminternational.com/view/cell-harvesting-steps-separate-the-good-from-the-bad (Accessed 20 February 2026).
- Trypsin. (2026). DrugBank. Available https://go.drugbank.com/drugs/DB11237 (Accessed 20 February 2026).
- Choosing Optimal Harvesting Solutions. (2023). Corning Inc. Available https://www.corning.com/catalog/cls/documents/application-notes/CLS-AN-634.pdf (Accessed 20 February 2026).
- Lordon, B, Campion, T, Gibot, L, Gallot, G, Impact of trypsin on cell cytoplasm during detachment of cells studied by terahertz sensing (2024), Biophys J 123, pp. 2476-83. doi: 10.1016/j.bpj.2024.06.011.
- Lai, TY, Cao, J, Ou-Yang, P, Tsai, CY, Lin, CW, Chen, CC, Tsai, MK, Lee, CY, Different methods of detaching adherent cells and their effects on the cell surface expression of Fas receptor and Fas ligand (2022), Sci Rep 12, pp. 1-8. doi: 10.1038/s41598-022-09605-y.
- Weber, C, Pohl, S, Pörtner, R, Wallrapp, C, Kassem, M, Geigle, P, Czermak, P, Expansion and Harvesting of hMSC-TERT (2007), Biomed Eng J 1, pp. 38-46. doi: 10.2174/1874120700701010038.
- Vertegel, P, Milkin, P, Murashko, A, Parker, M, Peranidze, K, Emashova, N, Minko, S, Reukov, V, Cell detachment: A review of techniques, challenges, and opportunities for advancing biomedical research and applications (2025), Prog Biophys Mol Biol 195, pp. 50-68. doi: 10.1016/j.pbiomolbio.2025.02.004.
- Lagerwall, C, Shahin, H, Abdallah, S, Steinvall, I, Elmasry, M, Sjöberg, F, El-Serafi, AT, Xeno-free workflow exhibits comparable efficiency and quality of keratinocytes isolated from human skin biopsies, Regen Ther 18, pp. 401-7. doi: 10.1016/j.reth.2021.09.005.
- Drescher, H, Weiskirchen, S, Weiskirchen, R, Flow Cytometry: A Blessing and a Curse (2021), Biomedicines 9, pp. 1-12. doi: 10.3390/biomedicines9111613.
- Overcoming Harvesting Challenges for Adherent Cell-Culture Processes. (2023). Cynthia A. Challener, BioPharm International. Available https://www.biopharminternational.com/view/overcoming-harvesting-challenges-for-adherent-cell-culture-processes (Accessed 23 February 2026).
